Clinical trials: Osler-Rendu Disease
Telangiectasia, Hereditary Hemorrhagic
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
This study will investigate whether pazopanib can reduce epistaxis and improve anaemia in subjects with hereditary haemorrhagic telangiectasia (HHT) at a dose that is well tolerated. The study will have 2 parts.
- Trial name
- NCT02204371
- Testing
- Pazopanib
- Where
- 6 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline